Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NCT05608044 trial: what clinicians have said so far
A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer
- NCT05608044 ↗
- Active, not recruiting
- Agenus Inc.
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on NCT05608044 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT05608044 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Open-Label, Phase 2 Study of Botensilimab (AGEN1181) as Monotherapy and in Combination With Balstilimab (AGEN2034) or Investigator's Choice Standard of Care (Regorafenib or Trifluridine and Tipiracil) for the Treatment of Refractory Metastatic Colorectal Cancer
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Botensilimab; Balstilimab; Standard of Care
- Arms
- Combination Botensilimab Dose 1 plus Balstilimab · Experimental
- Combination Botensilimab Dose 2 plus Balstilimab · Experimental
- Monotherapy Botensilimab Dose 1 · Experimental
- Monotherapy Botensilimab Dose 2 · Experimental
- Standard of Care · Active comparator
- Enrollment
- 234
- Primary outcomes
- Objective Response Rate
- Sponsor
- Agenus Inc.
- Start
- Nov 30, 2022
- Primary completion
- Sep 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05608044 · updated Nov 5, 2026